The advanced medical technology that we deploy at North Florida Regional Medical Center takes years of testing to get to where we are now. One of the most recent additions to the services at the Florida Heart and Lung Institute is known as COAPT, and took as long as 8 years to mature into what it is today. Here’s a quick brief on what the procedure entails and who may be qualified.

On September 23rd, 2018, the data on the study of this procedure was released with praise. The mortality rate at the 2-year period was at a comfortable low, while the primary endpoint of heart failure was significantly reduced.

The process of overhauling a traditional medical procedure lies in the results of its effectiveness. Statistical analysis is used to compare the clinical results after 2 years post operation. What doctors and researchers have ultimately found behind the COAPT procedure is that the Mitraclip procedure makes a substantial difference in the long-term health of the recipient. Endless data has been recorded on the matter, although a few shocking points stand out. Using the mortality rate two years after the operation gives a great understanding of what goes on long after the patient has left the operating room. The trials showed that this rate held steadily below 30%, while standard operations were around 50%. Compared to typical medical therapy after two years, COAPT patients exhibited 45.7% rehospitalization versus 67.9% This is one of the biggest findings, for it makes it likely that at least 20% of patients are benefitting heavily from this new form of treatment. Annual rates for this condition lie at 35.8% and versus 67.9%.

Dr. Charles T. Klodell and Thomas Zeyl are leading the pack in Gainesville when it comes to these percutaneous operations. By opting for these new procedures, our team can stay at the forefront of medical treatment while the community accesses it. Click here to read the extended findings behind the services offered by our Florida Heart & Lung Institute.